Further, and coincidentally, a long list of USA specialty groups just released a guideline on this topic reported at firstwatch.jwatch.org  (free full text story at http://cardiology.jwatch.org/cgi/content/full/2011/209/3?q=pfw-featuredm  ) which relies primarily on traditional risk factors and not on fancy tests…

 

Best

Rich


From: Evidence based health (EBH) [mailto:[log in to unmask]] On Behalf Of Richard Saitz
Sent: Sunday, February 13, 2011 4:47 PM
To: [log in to unmask]
Subject: Re: Question about screening and denominators

 

Hello Ash,

I am unfamiliar with said claptrap, but there are certainly a wide range of guidelines out there, and many ways to evaluate which should be followed versus ignored.  At the national level though, in the US, the plan is for coverage to be applied for preventive services only if they are rated A or B by the US Preventive Services Task Force.  The US Prev Services Task Force requires high quality evidence before making a recommendation.  Their recommendation re coronary disease appears below.

Best

Rich

Richard Saitz MD, MPH, FACP, FASAM

Editor, Evidence-based Medicine (EBM)

Professor of Medicine and Epidemiology

 

Summary of Recommendations

·                     The U.S. Preventive Services Task Force (USPSTF) recommends against routine screening with resting electrocardiography (ECG), exercise treadmill test (ETT), or electron-beam computerized tomography (EBCT) scanning for coronary calcium for either the presence of severe coronary artery stenosis (CAS) or the prediction of coronary heart disease (CHD) events in adults at low risk for CHD events.
Grade: D Recommendation.

·                     The USPSTF found insufficient evidence to recommend for or against routine screening with ECG, ETT, or EBCT scanning for coronary calcium for either the presence of severe CAS or the prediction of CHD events in adults at increased risk for CHD events.
Grade: I Statement.

 


From: Ash Paul [mailto:[log in to unmask]]
Sent: Sunday, February 13, 2011 2:14 AM
To: Richard Saitz; [log in to unmask]
Subject: Re: Question about screening and denominators

 

Dear Richard,

What about the claptrap being promoted by the Screening for Heart Attack Prevention and Education (SHAPE) Task Force in the USA?

The SHAPE Guideline calls for noninvasive screening of all asymptomatic men 45–75 years of age and asymptomatic women 55–75 years of age (except those defined as very low risk) to detect and treat those with subclinical atherosclerosis.
And now the Texas Government has fallen for this hook, line and sinker and passed into law a measure to provide reimbursement for MI screening.

Is it any wonder that the US healthcare system costs are spiralling out of control?

Regards,

 

 

 

Ash

Dr Ash Paul
Medical Director
NHS Bedfordshire

21 Kimbolton Road

Bedford

MK40 2AW

Tel no: 01234897224

 

 

 

 


From: Richard Saitz <[log in to unmask]>
To: [log in to unmask]
Sent: Sat, 12 February, 2011 21:49:15
Subject: Re: Question about screening and denominators

Simon,

One of my favorite examples of this issue was published in the NEJM in 1987, a classic. And still relevant today re HIV screening.  I’ll excerpt below and here is the reference:

 

Screening for HIV: Can We Afford the False Positive Rate?

Klemens B. Meyer, M.D., and Stephen G. Pauker, M.D.

N Engl J Med 1987; 317:238-241July 23, 1987

 

Bottom line re HIV testing example: 100% sensitive test, 99.995% specificity. Positive predictive value (chance the patient has the disease) of test if prevalence is 0.01%=67% (one third with a positive test don’t have the disease).

 

Best,

Rich Saitz

 

Richard Saitz MD, MPH, FACP, FASAM

Editor, Evidence-based Medicine (EBM)

Professor of Medicine and Epidemiology

 

http://ebm.bmj.com/ 

[log in to unmask]

 

PREVALENCE OF INFECTION

What do we know about the prevalence of HIV infection? Perhaps 50 percent of homosexual men in San Francisco have serologic evidence of the infection. The prevalence of seropositivity among intravenous drug abusers and among patients with hemophilia who received factor VIII concentrate pooled before the advent of heat inactivation is similar.3 , 8 At somewhat lower risk are patients who received repeated transfusions of red cells, platelets, and plasma before routine HIV testing of donated blood began in 1985. Antibody testing of one group of patients with leukemia treated between 1978 and 1985 showed that about 5 percent became seropositive. The patients who became seropositive had received an average of 164 units of blood products.26

Other segments of the population are at much lower risk. Screening of military recruits has shown 0.16 percent of the men and 0.06 percent of the women to be seropositive.27 When antibody screening of donated blood began in 1985, 1 unit of blood in 2500 had HIV antibody.28 At that rate, the chance of infection from 2 units of blood donated before antibody screening began would be about 0.08 percent. Among female blood donors, as noted, the reported prevalence of seropositivity is 0.01 percent. Some of these donors may have had sexual contact with members of known high-risk groups; among women without such contact, the prevalence of infection may be even lower than 0.01 percent.

MEANING OF POSITIVE TESTS

Test sensitivity is not the issue here, and to emphasize our concern with the false positive rate, our analysis makes the best-case assumption that the combination of enzyme immunoassay and Western blot testing for HIV is 100 percent sensitive, identifying all persons who are infected. The meaning of positive tests will depend on the joint false positive rate. Because we lack a gold standard, we do not know what that rate is now. We cannot know what it will be in a large-scale screening program. However, we can be fairly sure that without careful quality control, it will rise.

Bayes' rule allows us to calculate the probability that a person with positive tests is infected.29Imagine testing 100,000 people, among whom the prevalence of disease is 0.01 percent. Of the 100,000, 10 are infected; 99,990 are not. A combination of tests that is 100 percent sensitive will correctly identify all 10 who are infected. If the joint false positive rate is 0.005 percent, the tests will yield false positive results in 5 of the 99,990 people who are not infected. Thus, of the 15 positive results, 10 will come from people who are infected and 5 from people who are not infected, and the probability that infection is present in a patient with positive tests will be 67 percent.

 

 

 

 

 

 


From: Evidence based health (EBH) [mailto:[log in to unmask]] On Behalf Of Simon Hatcher
Sent: Wednesday, February 09, 2011 6:22 PM
To: [log in to unmask]
Subject: Question about screening and denominators

 

I had this discussion with a friend over a beer last night and we couldn't agree on the answer. Here's the scenario:

 

The incidence of a disease in a population is 1:1000

There is a test which correctly detects the disease 95%of the time

If I test positive with the test what is my risk of having the disease?

 

Be interested in any thoughts on the "correct" answer.

 

Cheers

 

Simon


 


______________________________________________________________________
This email has been scanned by the MessageLabs Email Security System.
For more information please visit http://www.messagelabs.com/email
______________________________________________________________________



______________________________________________________________________
This email has been scanned by the MessageLabs Email Security System.
For more information please visit http://www.messagelabs.com/email
______________________________________________________________________


_______________________________________________________________________
The BMJ Group is one of the world's most trusted providers of medical information for doctors, researchers, health care workers and patients group.bmj.com. This email and any attachments are confidential. If you have received this email in error, please delete it and kindly notify us. If the email contains personal views then the BMJ Group accepts no responsibility for these statements. The recipient should check this email and attachments for viruses because the BMJ Group accepts no liability for any damage caused by viruses. Emails sent or received by the BMJ Group may be monitored for size, traffic, distribution and content. BMJ Publishing Group Limited trading as BMJ Group. A private limited company, registered in England and Wales under registration number 03102371. Registered office: BMA House, Tavistock Square, London WC1H 9JR, UK.
_______________________________________________________________________

______________________________________________________________________
This email has been scanned by the MessageLabs Email Security System.
For more information please visit http://www.messagelabs.com/email
______________________________________________________________________